mRNA-based CAR T cell engineering: Unmodified mRNA enables high CAR expression without innate immune activation in T cells

Read full text
Authors: Nourhan Kahwaji, Niklas Kotzian, Jasmin Melissa Prinz, Yaolin Pu, Jonas Kath, Samira Picht, Anna Hiller, Antonia M Klaas, Charlotte Maeve Dunne, Michael Launspach, Andriko Palmowski, Arnd Kleyer
+8 more David Nils Simon, Dimitrios L. Wagner, Chantal Pichon, Gerhard Krönke, Michael Schmueck-Henneresse, Hans-Dieter Volk, Manfred Gossen, Norman Michael Drzeniek
Cited by: 5
References: 30

Abstract

Unmodified, uridine-containing mRNA is known to trigger antiviral immune responses, inflammatory signaling, and apoptosis in transfected cells. To avoid this and enable high expression, modified nucleosides such as N1-methylpseudouridine have become the gold standard for mRNA applications including T cell engineering, albeit at increased cost. Here, immune responses toward mRNA were evaluated across five primary human cell types. Remarkably, T cells, unlike other immune and non-immune cell types tested, exhibited no immune activation by unmodified mRNA. T cell viability and cytokine secretion remained unaffected, regardless of mRNA delivery method via lipid nanoparticles or electroporation. The absence of nucleotide modifications improved expression of chimeric antigen receptor (CAR) in activated T cells and CAR-T cell cytotoxic potency. By eliminating the need for mRNA-nucleoside modification in CAR-T cell engineering, our findings challenge existing paradigms and position mRNA as a non-inflammatory, minimally invasive and highly efficient tool for T cell engineering, while simplifying and reducing manufacturing cost.

Fields of Study & Subjects

CAR-T cell therapy research Immune Cell Function and Interaction CRISPR and Genetic Engineering

Publication details

Journal / source
Molecular Therapy — Nucleic Acids
Publisher
Elsevier BV
Volume
37
Issue
1
Pages
102805–102805
Publication date
5 January 2026
Language
EN